United States - English - NLM (National Library of Medicine)

quality care products, llc - tramadol hydrochloride (unii: 9n7r477wck) (tramadol - unii:39j1lgj30j) - tramadol hydrochloride tablets, usp are indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1)] , reserve tramadol hydrochloride tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]: - have not been tolerated or are not expected to be tolerated. - have not provided adequate analgesia or are not expected to provide adequate analgesia. tramadol hydrochloride tablets, usp are contraindicated for: -   all children younger than 12 years of age [ see warnings and precautions (5.4) ]. -   post-operative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

radiofarmacia de centroamerica s.a - fluodeoxiglucosa 18 f - fluodeoxiglucosa 18 f....15 mci/0.55 gbq a 3ci/111 gbq en 3 ml a 19 ml

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - interferon alfa-2a 18 miu - powder for injection - 18 miu - active: interferon alfa-2a 18 miu excipient: albumin sodium chloride water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

orion pharma (nz) limited - carbidopa monohydrate 20.25mg equivalent to 18.75 mg carbidopa; entacapone 200mg; levodopa 75mg - film coated tablet - 75mg/18.75mg/200mg - active: carbidopa monohydrate 20.25mg equivalent to 18.75 mg carbidopa entacapone 200mg levodopa 75mg excipient: croscarmellose sodium ethanol glycerol hypromellose iron oxide red magnesium stearate   maize starch mannitol polysorbate 80 povidone purified water sucrose titanium dioxide - stalevo is indicated for the treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

Ireland - English - HPRA (Health Products Regulatory Authority)

leo laboratories limited - tinzaparin sodium - solution for injection - 18,000 iu in 0.9 ml international unit(s)/millilitre - heparin group; tinzaparin

Ireland - English - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - tiotropium - inhalation powder, hard capsule - 18 microgram(s) - anticholinergics; tiotropium bromide

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - tiotropium - inhalation powder, hard capsule - 18 microgram(s) - anticholinergics; tiotropium bromide

Ireland - English - HPRA (Health Products Regulatory Authority)

imbat limited - tiotropium bromide - inhalation powder, hard capsule - 18 microgram(s) - anticholinergics; tiotropium bromide

Ireland - English - HPRA (Health Products Regulatory Authority)

boehringer ingelheim international gmbh - tiotropium - inhalation powder, hard capsule - 18 microgram(s) - anticholinergics; tiotropium bromide

European Union - English - EMA (European Medicines Agency)

hospira uk limited - docetaxel trihydrate - stomach neoplasms; prostatic neoplasms; breast neoplasms; head and neck neoplasms; carcinoma, non-small-cell lung - antineoplastic agents - breast cancertaxespira in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.for patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.taxespira in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.taxespira monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.taxespira combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express her2 and who previously have not received chemotherapy for metastatic disease.taxespira in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline.non-small cell lung cancer taxespira indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.taxespira in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.prostate cancer taxespira in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.gastric adenocarcinoma taxespira in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.head and neck cancer taxespira in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.